UGT1A1 rs2812273: Bilirubin Levels and Gilbert Syndrome
rs2812273 is a common single nucleotide polymorphism located in the UGT1A gene cluster on chromosome 2. It has been evaluated in population genetics and association studies for its statistical relationship with circulating total bilirubin levels. Because of its genomic location near UGT1A1, researchers frequently assess its role in Gilbert syndrome susceptibility and liver clearance traits.
What each genotype means
Typical bilirubin metabolism
This genotype represents the most common form of the UGT1A1 gene, which is associated with standard enzyme activity for processing bilirubin. Individuals with this profile typically maintain normal serum bilirubin levels and are not at an increased genetic risk for Gilbert syndrome.
This is the most common genotype in many global populations, though frequencies vary significantly by ancestry.
Reduced enzyme activity carrier
Carrying one copy of the variant allele may result in slightly reduced UGT1A1 enzyme activity compared to those without the variant. While this is generally not sufficient to cause Gilbert syndrome, it may influence how your body processes bilirubin under conditions of stress, fasting, or illness. Please discuss any concerns regarding bilirubin levels or medication metabolism with your clinician or pharmacist.
This heterozygous genotype is common, appearing in a significant portion of the population depending on ethnic background.
Increased Gilbert syndrome risk
This genotype is associated with significantly reduced UGT1A1 enzyme activity, which can lead to elevated levels of unconjugated bilirubin in the blood. This profile is a primary genetic factor for Gilbert syndrome, a condition that may cause mild jaundice during periods of stress, dehydration, or fasting. Please consult with your healthcare provider to discuss your bilirubin levels and any potential implications for medication dosing.
This homozygous genotype is less common than the heterozygous form but is a well-documented genetic marker for Gilbert syndrome across various populations.
Genomic Location and the UGT1A Cluster
The single nucleotide polymorphism rs2812273 resides on chromosome 2 within the complex UGT1A gene locus. This chromosomal region features a cluster of shared and unique exons that encode several UDP-glucuronosyltransferase enzymes, primarily governed by alternative promoter usage. Variants mapped across this locus often track together through linkage disequilibrium, meaning that non-coding or intronic changes like rs2812273 frequently co-occur with well-characterized regulatory alleles such as UGT1A1*28. Understanding the exact chromosomal position of rs2812273 helps researchers decipher whether observed physiological effects stem directly from the variant itself or reflect broader haplotypic patterns across the UGT1A cluster.
Biological Function of UGT1A1 and Glucuronidation
The UGT1A1 enzyme plays an essential role in hepatic clearance by catalyzing glucuronidation, a major phase II detoxification reaction. Its primary endogenous substrate is unconjugated bilirubin, a potentially neurotoxic byproduct formed during the breakdown of hemoglobin from aging red blood cells. By conjugating bilirubin with glucuronic acid, UGT1A1 renders it water-soluble, allowing safe excretion via bile into the digestive tract. Beyond endogenous compounds, the enzyme facilitates the clearance of numerous pharmaceuticals and environmental chemicals. Disruptions or variations in the gene can alter baseline enzyme capacity, directly influencing circulating bilirubin levels and drug metabolism efficiency.
Research Evidence: Bilirubin and Gilbert Syndrome
Studies assessing quantitative traits have identified rs2812273 in connection with variation in serum total bilirubin concentrations. Elevated unconjugated bilirubin without underlying liver disease or hemolysis is the hallmark of Gilbert syndrome, a benign genetic condition. However, current genomic databases classify the clinical evidence for rs2812273 as limited. While population studies demonstrate statistically significant associations with bilirubin shifts, the variant is generally considered an indirect marker rather than an established independent causal mutation. Major regulatory variants, such as the UGT1A1*28 promoter repeat or coding mutations like UGT1A1*6, remain the primary functional drivers characterized in clinical literature.
Population Frequency and Context
Variant rs2812273 is widely distributed across global populations, with the minor allele displaying frequencies typically ranging between 0.30 and 0.45 depending on the ancestral group. This widespread prevalence mirrors the common occurrence of benign unconjugated hyperbilirubinemia in human cohorts worldwide. Because allele frequencies across the broader UGT1A locus vary substantially—such as the differing geographic distribution seen between European cohorts carrying promoter repeats and East Asian populations with missense variants—interpreting rs2812273 requires careful consideration of ancestral background and regional genetic architecture.
Practical Implications for Health and Wellness
Learning your genotype at rs2812273 provides educational insight into metabolic diversity rather than a clinical diagnosis. Bilirubin levels naturally fluctuate in response to fasting, physical exertion, illness, and dehydration. A genetic marker showing an association with higher bilirubin does not confirm a liver disorder, nor does a standard genotype guarantee that bilirubin will remain within standard laboratory reference ranges. Furthermore, because UGT1A1 influences the processing of specific therapeutic drugs, any questions regarding laboratory liver panels or personalized pharmacotherapy should be discussed directly with a qualified physician or clinical pharmacist.
How common is this variant?
The minor allele frequency for rs2812273 ranges from 0.30 to 0.45 across global populations, demonstrating that this genetic variation is common across diverse ancestries.
Frequently asked questions
What is the primary function of the UGT1A1 gene?
The UGT1A1 gene encodes an enzyme that facilitates glucuronidation, a process that converts fat-soluble compounds into water-soluble forms. It is essential for clearing unconjugated bilirubin, a natural byproduct of red blood cell breakdown, allowing it to be safely excreted into bile.
Does having rs2812273 mean I have Gilbert syndrome?
No, carrying this variant does not mean you have Gilbert syndrome. While rs2812273 is statistically linked to elevated bilirubin levels, scientific evidence classifies its independent clinical impact as limited, and formal diagnoses require professional medical evaluation and laboratory blood work.
Why does bilirubin rise during fasting or illness?
Bilirubin levels fluctuate naturally in response to physiological stressors such as dehydration, prolonged fasting, intense physical exercise, or mild infections. In individuals with lower baseline UGT1A1 enzyme activity, these stressors can transiently decrease clearance capacity and cause noticeable spikes in unconjugated bilirubin.
Can this genetic variant affect how I metabolize medications?
The UGT1A1 pathway is involved in processing certain pharmaceuticals, including specific oncology drugs and antivirals. While rs2812273 is located in this cluster, medication dosing decisions are guided by specific, validated clinical pharmacogenetic guidelines; you should always consult a clinician or pharmacist before altering any regimen.
Sources & further reading
Educational information only, last refreshed 9/8/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs2812273?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in UGT1A1
Missense variant corresponding to the functional UGT1A1*27 allele associated with reduced glucuronidation and elevated irinotecan toxicity risk.
Variant allele in UGT1A1 promoter region associated with altered glucuronidation and risk of irinotecan-induced toxicity.
Missense alteration associated with reduced glucuronidation capacity and increased susceptibility to irinotecan toxicity and hyperbilirubinemia.
This variant (UGT1A1*6) is a decreased-function allele associated with reduced glucuronidation capacity, impacting the metabolism of drugs like irinotecan and influencing neonatal hyperbilirubinemia risk.
This variant is a key marker for defining UGT1A1 star alleles (*1, *28, *36, *37) which influence the metabolism of drugs like irinotecan and the risk of hyperbilirubinemia.
This variant is associated with hyperbilirubinaemia (Gilbert's syndrome) and is used to guide irinotecan dosage.